Comprehensive Evaluation of Biological Age Post-Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer Patients - Scorecard - MDSpire

Comprehensive Evaluation of Biological Age Post-Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer Patients

  • By

  • Grace Lee

  • Fridolin Haugg

  • Dennis Bontempi

  • John He

  • Danielle S. Bitterman

  • Suraj Pai

  • Christian Guthier

  • Kelly J. Fitzgerald

  • David E. Kozono

  • Benjamin H. Kann

  • Hugo J. W. L. Aerts

  • Raymond H. Mak

  • April 8, 2026

  • 0 min

Share

Clinical Scorecard: Comprehensive Evaluation of Biological Age Post-Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer Patients

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients aged 60 years and older with early-stage NSCLC undergoing SBRT, as per study inclusion criteria.
Care Setting

Key Highlights

  • Add context on the clinical implications of deep learning models for biological age estimation.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Follow-up with chest CT scans and oncologist visits every 6 months for the first 2 years, with specific imaging techniques outlined.

      Risks

        Patient & Prescribing Data

        Patients aged 60 years and older with early-stage NSCLC.

        Biologically younger patients may benefit more from curative-intent SBRT.

        Clinical Best Practices

        • Cite evidence or references that support the use of biological age assessments in treatment planning.

        References

        Original Source(s)

        Comprehensive Evaluation of Biological Age Post-Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer Patients

        • by Grace Lee, Fridolin Haugg, Dennis Bontempi, John He, Danielle S. Bitterman, Suraj Pai, Christian Guthier, Kelly J. Fitzgerald, David E. Kozono, Benjamin H. Kann, Hugo J. W. L. Aerts, Raymond H. Mak

        • April 8, 2026

        Related Content

        Imaging features of lung cancer with cystic airspaces: clinical utility, challenges, and perspectives

        Accelerated Immuno Chemoradiotherapy Based on FDG-PET/CT for Small Volume in Locally Advanced NSCLC (PACCELIO) – A Phase II Multicenter Randomized Open-Label Trial Protocol

        Mandatory Training Modules Deserve a Harder Look

        A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.